Last reviewed · How we verify
HLA-G-CAR.BiTE allogeneic γδ T cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
HLA-G-CAR.BiTE allogeneic γδ T cells (HLA-G-CAR.BiTE allogeneic γδ T cells) — Ever Supreme Bio Technology Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HLA-G-CAR.BiTE allogeneic γδ T cells TARGET | HLA-G-CAR.BiTE allogeneic γδ T cells | Ever Supreme Bio Technology Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HLA-G-CAR.BiTE allogeneic γδ T cells CI watch — RSS
- HLA-G-CAR.BiTE allogeneic γδ T cells CI watch — Atom
- HLA-G-CAR.BiTE allogeneic γδ T cells CI watch — JSON
- HLA-G-CAR.BiTE allogeneic γδ T cells alone — RSS
Cite this brief
Drug Landscape (2026). HLA-G-CAR.BiTE allogeneic γδ T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/hla-g-car-bite-allogeneic-t-cells. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab